🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 New paper 🚨 🌏What evidence exists concerning the delivery of #palliative & end-of-life care to #AYACancer patients? 👇Here's what we found out! doi.org/10.1089/jayao.… #AYACSM #MedTwitter #RadOnc #PallOnc #BTSM #BCSM #GlobOnc #PedOnc

Congrats to Ryan Denu, MD, PhD and our group at MD Anderson Cancer Center Vivek Subbiah, MD Kadir C Akdemir Valerae Lewis, MD Ravin Ratan Andy Livingston, MD MS mIDH is more common in extremities, older age, and in dedifferentiated #chondrosarcoma. mTP53 but not mIDH is prognostic. aacrjournals.org/clincancerres/…

A study led by our Dr. Anthony Conley finds a TP53 gene mutation is linked to poorer overall survival and outcomes in patients with chondrosarcoma. Learn more: brnw.ch/21wE4jr CURE Today Anthony P Conley #EndCancer

Important #osteosarcoma trial results reported at #CTOS2023! Visit Poster 166 SARC038: A PHASE 2 STUDY OF REGORAFENIB IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA cdmcd.co/EdpBQv

Initial data with intratumoral TGFb trap in multiple tumor types, including multiple patients with #STS #sarcoma #chordoma

Drugs targeting master regulators in osteosarcoma! Looking forward validation of Rel/NFkb Class II HDAC BetaCatenin/TBL1 CDK2/5/9 EZH2/EZH1 ATM/ATR inhibitors! Well done Jovana Pavisic, MD, MA! CTOS #CTOS2023 Katie Janeway

Addressing an all too common problem — radiation in multiD plan for #STS following unplanned excision. 5y LC associated with final margins and preop RT prior to re-excision MD Anderson Cancer Center SunDog #CTOS2023

Excellent work presented by Katie Janeway helps answer the question we ask in just published osteosarcoma review mdpi.com/2072-6694/15/2… Lara Davis Fred Hutch Cancer Center Dana-Farber @Lawlorlab The Osteosarcoma Institute MIB Agents Osteosarcoma Alliance

Congratulations to our 2nd year #surgonc fellows for their posters #CTOS2023 Alicia Gingrich: preliminary analyses of immune deconvolution of RNAseq in #LMS @MadelineBTorres: our experience with #immunotherapy in DDLPS Thank you for your hard work 🙏🏻 MD Anderson Cancer Center

Congratulations on your impressive work! #CTOS2023

#CTOS2023 - Temozolomide shows activity in patients with SDH-deficient in a prospective phase II trial Jon Trent, MD, PhD Sylvester Comprehensive Cancer Center

Can intratumoral oncolytic therapy induce regression of distant mets? Check out this example involving an #LMS patient on trial. #sarcoma Molecular Cancer Therapeutics EpicentRx, Inc. MD Anderson Cancer Center Vivek Subbiah, MD aacrjournals.org/mct/article/23…

Exciting to see this out. Cell therapy for solid tumors. #Sarcoma paving the way. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial ⁦Adaptimmune⁩ thelancet.com/journals/lance…

The incidence of angiosarcoma is increasing in the US with >1000 new cases per year. The overall increase is driven by a higher incidence rate of secondary breast and chest wall angiosarcomas in women, finds retrospective cross-sectional study. ja.ma/443X3nS

Two #SARCtrials have been selected for oral presentation at #ASCO24. SARC032 and SARC037 will be presented Monday, June 3rd during the #sarcoma session from 3-6pm CDT. See more here: sarctrials.org/sarc-sponsored… #ASCO2024 #ASCO #clinicaltrial

✨so proud of Emily Keung, MD MD Anderson Cancer Center and Florent Petitprez 🇫🇷 overview and presentation of #TLS as a predictive bio marker for #immunotherapy in #sarcoma #ASCO24 Great SARC session chaired by Sandra P D'Angelo, MD

Great talk by Florent Petitprez on predictive IO biomarkers in #sarcoma at #ASCO24 ❌TMB is impractical ❌MMRd is impractical ⁉️PD-L1 needs to be validated ❗️Histotype matters, but only part of the story ‼️Tumor microenviroment is the future: TLS, SICs, Treg cells